

Please type a plus sign (+) inside this box →

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number 10/080,526  
Filing Date February 21, 2002  
First Named Inventor SHUDO, JUTARO  
Group Art Unit 1615  
Examiner Name To be assigned  
Attorney Docket Number TEIK-004

RECEIVED

DEC 05 2002

TECH CENTER 1600/2900

## U.S. PATENT DOCUMENTS

Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	U.S. Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
24		5,846,559		Hopp	12-08-1998	
24		4,214,592		Jacquet <i>et al.</i>	07-29-1980	
27		4,129,647		Klein	12-12-1978	

## FOREIGN PATENT DOCUMENTS

Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Foreign Patent Documents			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
20		EP	1170020	A	Yamasaki <i>et al.</i>	01-09-2002		
20		EP	0782861	A	Hirano <i>et al.</i>	07-09-1997		
21		EP	1029542	A	Ohtsuki <i>et al.</i>	08-23-2000		

## OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS

Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
20		STRICKER <i>et al.</i> "Decrease in viral load associated with topical dinitrochlorobenzene therapy in HIV disease" <i>Res Virol</i> (1997) 148:343-348 ✓	
24		ORACION <i>et al.</i> "DNCEB treatment of HIV-infected patients leads to beneficial immunologic outcomes, reduced viral load, and improved measures of quality-of-life" <i>J. Invest Dermatol.</i> (1998) 110:476 ✓	

Examiner Signature	<i>Sir Ghaer</i>	Date Considered	09/20/03
-----------------------	------------------	--------------------	----------


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard St.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box



RECEIVED

JUN 18 2002

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO			<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			Application Number	10/080,526
			Filing Date	February 21, 2002
			First Named Inventor	SHUDO, JUTARO
			Group Art Unit	1615
			Examiner Name	Unassigned
			Attorney Docket Number	TEIK-004
Sheet	1	of	1	

U.S. PATENT DOCUMENTS						
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	U.S. Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Foreign Patent Documents			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
28	✓	STRICKER et al. "Dendritic cells and dinitrochlorobenzene (DNCB): A new treatment approach to AIDS" <i>Immunol Letter</i> (1991) 29:191-196	✓
3	✓	STRICKER et al. "Pilot study of topical dinitrochlorobenzene (DNCB) in human immuno deficiency virus infection" <i>Immunol Letters</i> , (1993) 36:1-6	✓
1	✓	STRICKER et al. "Topical dinitrochlorobenzene in HIV disease" <i>J. Am. Acad Dermatol</i> (1993) 28:796-797	✓
	✓	STRICKER et al. "Clinical and immunologic evaluation of HIV-infected patients treated with dinitrochlorobenzene (DNCB). <i>J. Am. Acad Dermatol</i> (1994) 31:462-466	✓
	✓	STRICKER et al. "Improved results of delayed-type hypersensitivity skin testing in HIV-infected patients treated with topical dinitrochlorobenzene (DNCB). <i>J. Acad Dermatol.</i> (1995) 33:608-611	✓
	✓	STRICKER AND GOLDBERG "Safety of topical dinitrochlorbenzene Lancet" (1995) Vol. 346 pp. 1293	✓
	✓	STRICKER et al. "Improved results of delayed-type hypersensitivity skin testing in HIV-infected patients treated with topical dinitrochlorobenzene" <i>J. Am Acad Dermatol</i> (1996) 35:491-493	✓
	✓	STRICKER et al. "Decrease in viral load associated with topical dinitrochlorobenzene therapy in HIV disease" <i>Res Virol</i> (1997) 148:343-348	✓
	✓	TRAUB et al. "Topical immune modulation with dinitrochlorobenzene (DNCB) in HIV disease: A controlled trial from Brazil" <i>Dermatology</i> (1997) 195:369-373	✓
✓	✓	STRICKER et al. "Topical immune modulation (TIM): A novel approach to the immunotherapy of systemic disease" <i>Immunol Letters</i> (1997) 59:145-150	✓
4	✓	ORACION et al. "DNCB treatment of HIV-infected patients leads to beneficial immunologic outcomes, reduced viral load, and improved measures of quality-of-life" <i>J. Invest Dermatol.</i> (1997) 110:476	✓

Examiner Signature	<i>Lis Ghal</i>	Date Considered	09/20/03
-----------------------	-----------------	--------------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.